G1 Therapeutics, Inc. (GTHX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GTHX POWR Grades
- GTHX scores best on the Value dimension, with a Value rank ahead of 58.46% of US stocks.
- GTHX's strongest trending metric is Growth; it's been moving down over the last 161 days.
- GTHX ranks lowest in Growth; there it ranks in the 1st percentile.
GTHX Stock Summary
- As for revenue growth, note that GTHX's revenue has grown 58.75% over the past 12 months; that beats the revenue growth of 88.01% of US companies in our set.
- The volatility of G1 Therapeutics Inc's share price is greater than that of 88.39% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GTHX comes in at -26.49% -- higher than that of only 13.85% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to G1 Therapeutics Inc are AFIB, CLIR, AAOI, KOPN, and FUV.
- Visit GTHX's SEC page to see the company's official filings. To visit the company's web site, go to www.g1therapeutics.com.
GTHX Valuation Summary
- In comparison to the median Healthcare stock, GTHX's price/earnings ratio is 116.99% lower, now standing at -6.2.
- GTHX's price/sales ratio has moved NA NA over the prior 52 months.
- GTHX's price/earnings ratio has moved up 2.8 over the prior 52 months.
Below are key valuation metrics over time for GTHX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GTHX | 2021-08-31 | 10.0 | 3.0 | -6.2 | -4.4 |
| GTHX | 2021-08-30 | 9.7 | 2.9 | -6.0 | -4.2 |
| GTHX | 2021-08-27 | 9.7 | 2.9 | -6.1 | -4.3 |
| GTHX | 2021-08-26 | 9.4 | 2.8 | -5.8 | -4.0 |
| GTHX | 2021-08-25 | 9.7 | 2.9 | -6.0 | -4.2 |
| GTHX | 2021-08-24 | 9.5 | 2.8 | -5.9 | -4.1 |
GTHX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GTHX has a Quality Grade of D, ranking ahead of 22.6% of graded US stocks.
- GTHX's asset turnover comes in at 0.239 -- ranking 181st of 681 Pharmaceutical Products stocks.
- NVAX, SRRA, and OCX are the stocks whose asset turnover ratios are most correlated with GTHX.
The table below shows GTHX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.239 | 0.984 | -3.150 |
| 2021-03-31 | 0.219 | 0.996 | -3.451 |
| 2020-12-31 | 0.182 | 1.000 | -5.667 |
| 2020-09-30 | 0.101 | 1.000 | -9.018 |
| 2020-06-30 | 0.000 | NA | -13.386 |
| 2020-03-31 | 0.000 | NA | -148.700 |
GTHX Price Target
For more insight on analysts targets of GTHX, see our GTHX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $50.86 | Average Broker Recommendation | 1.44 (Moderate Buy) |
GTHX Stock Price Chart Interactive Chart >
GTHX Price/Volume Stats
| Current price | $9.01 | 52-week high | $37.07 |
| Prev. close | $9.07 | 52-week low | $9.00 |
| Day low | $9.00 | Volume | 605,952 |
| Day high | $9.72 | Avg. volume | 792,358 |
| 50-day MA | $11.48 | Dividend yield | N/A |
| 200-day MA | $16.42 | Market Cap | 383.12M |
G1 Therapeutics, Inc. (GTHX) Company Bio
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company was founded in 2008 and is based in Research Triangle Park, North Carolina.
Latest GTHX News From Around the Web
Below are the latest news stories about G1 Therapeutics Inc that investors may wish to consider to help them evaluate GTHX as an investment opportunity.
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January. G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January |
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), and an aggregate of 50,200 shares of G1’s common stock to seven employees under the previously-announced G1 Therapeutics, Inc. |
Analysts Are Bullish on Top Healthcare Stocks: Sierra Oncology (SRRA), G1 Therapeutics (GTHX)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sierra Oncology (SRRA – Research Report), G1 Therapeutics (GTHX – Research Report) and Rubius Therapeutics (RUBY – Research Report) with bullish sentiments. Sierra Oncology (SRRA) In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sierra Oncology, with a price target of $35.00. The company's shares closed last Thursday at $22.29, close to its 52-week high of $24.00. According to TipRanks. |
Needham Thinks G1 Therapeutics’ Stock is Going to RecoverNeedham analyst Gil Blum maintained a Buy rating on G1 Therapeutics (GTHX – Research Report) today and set a price target of $44.00. The company's shares closed last Thursday at $10.16, close to its 52-week low of $9.75. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.8% and a 6.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for G1 Therapeutics with a $38.83 average price target. |
GTHX Price Returns
| 1-mo | -16.88% |
| 3-mo | -33.80% |
| 6-mo | -49.01% |
| 1-year | -57.07% |
| 3-year | -55.24% |
| 5-year | N/A |
| YTD | -11.75% |
| 2021 | -43.25% |
| 2020 | -31.93% |
| 2019 | 38.02% |
| 2018 | -3.48% |
| 2017 | N/A |
Loading social stream, please wait...